Solvay Pharma Россия и СНГ Обратная связь Карта сайта
Воскресенье, 4 января 2009 г.
Сделать стартовойДобавить в избранноеСообщить о странице другуW@PAvantGoPDA
В стремлении к прогрессу, с заботой о людях
Креон
Регистрация
XV Российский национальный конгресс "Человек и лекарство"

Библиография

Включен в программу ОНЛС

  1. Abiodun P, Tolckmitt W. Zur Behandlung der Pankreasinsuffizienz bei Mucoviscidose. (Treatment of pancreatic insufficiency associated with cystic fibrosis.) Kinderarzt 1982; 13: 1887-1894.
  2. Ahrens R, Hartmann F. Pankreasdysfermentien bei Hepatitis, Cholangitis und latenter Hepatopathie. (Functional disorders of the pancreas with hepatitis, Cholangitis and latent hepatopathy.) Klin. Wochenschr. 1952; 30 (5/6): 103-105.
  3. Ammann R. Langzeitverlauf und Therapie der chronisch-rezidivierenden Pankreatitis. (Long-term development and therapy of chronic relapsing pancreatitis.) Internist 1979; 20: 392-398.
  4. Aparisi L, Rodrigo JM, Serra MA, Del Olmo J, Bisquert M, у Raga F. Estudio de la eficacia de una nueva pancreatina microencapsulada frente a un preparado convencional, en el tratamiento de la esteatorrea de origen pancreatico. Rev. Esp. Enf. Ap. Digest. 1989; 76 (1): 25-30.
  5. Backes G. Wirksamkeitsvergleich neuer magensaftresistenter Pankreasenzympraparate in mikroverkapselter Form. (Comparison of efficacy between new acid-resistant micro-encapsulated pancreatic enzyme preparations.) Therapiewoche 1986; 36 (18): 1901-1904.
  6. Balzer E, Werner K. Untersuchungen uber die Eignung von Fermentpraparaten fur die Substitution von Pankreasfermenten. (Investigations of enzyme preparations for pancreatic enzyme replacement therapy.) Med. Klin. 1953; 29:1036-1038.
  7. Balzer E, Werner K. Weitere Untersuchungen uber die Eignung von Pankreaspraparaten fur die Substitution von Pankreasfermenten. (Additional investigations of enzyme preparations for pancreatic enzyme replacement therapy.) Munch. Med. Wochenschr. 1954; 47: 1386-1387.
  8. Beck K. Vergleichende Untersuchungen von Pankreasfermentpraparaten an Pankreaslosen. (Comparative investigations of pancreatic enzyme preparations after pancreatectomy.) Dissertation: Grossehelleforth 1971.
  9. Becker V. Pathologische Anatomie praktisch wichtiger Pankreas-Erkrankungen. (Pathological anatomy of practically important pancreatic disorders.) Dtsch. Med. J. 1972; 23 (9): 558-562.
  10. Bender St W, Stephan U. Behandlung der Verdauungsstorung bei Mucoviscidose. (Treatment of maldigestion associated with cystic fibrosis.) Kinderarzt 1979; 10(7): 999-1000.
  11. Berger HG. Chirurgische Therapie der akuten Pankreatitis - Indikationen, Ergebnisse, Probleme. (Surgical therapy of acute pancreatitis - indications, results, problems.) 99. Tagung Nordwestdtsch. Ges. f. Innere Medizin (Braunschweig 24.-2S. 06. 1982) Kongressbericnt: 16-17.
  12. Berlin CP, von der Hardt H, Muller W, Steinkamp G, Tummler B. Verwendung mikroverkapselter Pankreasenzympraparate bei Kindern mit Mukoviszidose. (Administration of micro-encapsulated pancreatic enzyme preparations in children with cystic fibrosis.) Therapiewoche 1988; 38: 818-829.
  13. Beverley DW, Kelleher J, MacDonald A, Littlewood JM, Robinson T, Walters MP. Comparison of four different pancreatic extracts in cystic fibrosis. Arch. Dis. Childhood 1987; 62: 564-568.
  14. Biermann H, Wendlberger H, Brockmann P, Tittor W. Durch modifizierten Saureschutz Verbesserung der Enzymtherapie bei Pankreasinsuffizienz. (Improvement of enzyme substitution in pancreatic insufficiency due to modification of the protection against gastric acid.) Med. Welt 1985; 36: 92-95.
  15. Brackmann P, Ruther HG. Die digestive Wirkung sauregeschutzter Lipase bei pankreatogener Steatorrhoe. (The digestive efficacy of acid-protected lipase in pancreatic induced steatorrhoea.) Fortschr. Med. 1984; 44: 1143-1145. CREON (High lipase pancreatin). A product profile. Reid-Rowell1988.
  16. Creutzfeldt W, Lankisch PG. Totale Duodenopankreatektomie bei chronischer Pankreatitis. (Total duodenopancreatectomy for chronic pancreatitis.) Z. Gastroenterol. 1980; 18: 641-643.
  17. DiMagno EP, Malagelada JR, Go VL, Moertel ChG. Fate of orally ingested enzymes in pancreatic insufficiency. N. Engl. J. Med. 1977; 296 (23): 1318-1322.
  18. Dockter G. Klinik der Mukoviszidose. (Cystic fibrosis.) Med. Welt 1990; 41: 213-217.
  19. During G. Pseudomonas-aeruginosa-Lungeninfektion bei Patienten mil Mukoviszidose - neue Erkenntnisse. (Lung infection with Pseudomonas aeruginosa in cystic fibrosis patients - latest results.) Med. Welt 1990; 41: 226-230.
  20. Drube HCh. Untersuchungen zur medikamentosen Therapie der Verdauungsinsuffizienz. (Investigations of medicinal therapy of digestive insufficiency.) Z. Gastroenterol. 1963; 1: 358-366.
  21. Duhamel JM, Vidailhet M, LeLuyer B, Douchain F, Jehanne M, Clavel R, Guillot M. Etude multicentrique comparative d'une nouvelle presentation de pancreatine en microgranules gastroresistants dans l'insuffisance pancreatique exocrine de la mucoviscidose chez l'enfant. (Multicentre comparative study with a new enteric-coated, acid-protected microgranulated pancreatin preparation in children with pancreatic exocrine insufficiency caused by cystic fibrosis.) Ann. Pediatr. 1988; 35, 1.
  22. Forell MM, Stahlheber H, Otte M. Erkrankungen der Verdauungsorgane und ihr Einflu? auf die Pankreassekretion. (Disorders of intestinal tract and their influence on pancreatic secretion.) Dtsch. Med. Wochenschr. 1969; 94 (21): 1097-1101.
  23. Freise J, Horstkotte H. Exocrine Pankreasinsuffizienz. Vergleich einer Substitutionstherapie mit nichtsaureresistenten und einer saureresistenten Enzympraparation. (Deficiency of exocrine pancreas: comparison of substitution therapy with non-acid resistant and resistant enzyme replacement.)
  24. Fortschr. Med. 1986; 104 (33): 625-628. George DE, Toskes PP, Sitren HS, Downey LJ. Comparison of two pancreatic enzyme supplements in patients with cystic fibrosis. Adv. Therapy 1990; 7 (3): 109-118.
  25. Goebell H, Bode Ch, Lepler U, Martini GA. Funktionsuntersuchungen des exokrinen Pankreas bei Leberzirrhosen verschiedener Atiologie, Hamochromatose und nach portokavalem Shunt. (Investigations of the exocrine pancreatic function associated with hepatic cirrhosis of various etiologies, hemochromatosis and after portocaval shunt.) Acta hepato-splenol. 1971; 18 (6): 437-452.
  26. Goodchild MC, Dodge JA. Cystic Fibrosis. Manual of diagnosis and management. Bailliere Tindall 1985.
  27. Gretzmacher I, Ruther HG. Maldigestion. (Maldigestion.) Therapiewoche 1983; 33 (50): 6676-6782.
  28. Gullo L, Barbara L, Labo G. Effect of cessation of alcohol use on the course of pancreatic dysfunction in alcoholic pancreatitis. Gastroenterol. 1988; 95:1063-1068.
  29. Hendeles L, Dorf A, Stecenko A, Weinberger M. Treatment failure after substitution of generic pancrelipase capsules: correlation with in vitro lipase activity. JAMA 1990; 263: 2459-2461.
  30. Henker J, Hein J, Vogt L, Paditz E. Mukoviszidose bei Kindern. Vergleich der Wirksamkeit zweier Pankreatinpraparate. (Cystic fibrosis in children. Comparison of the efficacy of two different pancreatic enzyme preparations.) Therapiewoche 1989; 39 (31/32): 2226-2229.
  31. Heptner G, Domschke S, Domschke W. Exocrine pancreatic function after gastrectomy. Gastroenterol. 1989; 97: 147-153.
  32. Herrerias JM, Gomez Parra M, Garcia Monies JM, Petit MA, Valladolid Leon JM. Estudio comparative cruzado entre pancreatina en "pellets" у pancreatina en tabletas en pancreatitis cronica. (Comparative crossover study of pancreatin in pellets and pancreatin in tablets in chronic pancreatitis.) Rev. Esp. Enf. Ap. Digest. 1989; 76 (6-II): 651-653.
  33. Hotz J. Neue Aspekte bei entzundlichen Pankreaserkrankungen. (New aspects of inflammatory pancreatic disorders.) Fortschr. Med. 1981; 99 (8): 253-261.
  34. Hotz J. Schmerzreiche Intervalle konservativ uberbrucken. (Conservative treatment of intermittent pancreatic pain.) Klinikarzt 1982; 11:267-270.
  35. Hotz J, Ho SB, Go VL, DiMagno EP. Short-term inhibition of duodenal tryptic activity does not affect human pancreatic, biliary or gastric function. J. Lab. Clin. Med. 1983; 101 (3): 488-495.
  36. Isaksson G, Ihse J. Pain reduction by an oral pancreatic enzyme preparation in chronic pancreatitis. Dig. Dis. Sci. 1983; 28 (2): 97-102.
  37. Kasper H. Interne Therapie der chronischen Pankreatitis und ihrer Folgen. (Medicinal therapy of chronic pancreatitis and its consequences.) Gastroenterol. Reihe 1978; 7: 85-95.
  38. Kolbel Ch, Layer P, Hotz J, Goebell H. Der Einfluss eines sauregeschutzten, mikroverkapselten Pankreatinpraparats auf die pankreatogene Steatorrhoe. (Influence of an enteric-coated micro-encapsulated pancreatin product on pancreatogenic steatorrhoea.) Med. Klinik 1986; 81 (3): 85-86.
  39. Kozuschek W, Reith HB. Pankreas-Erkrankungen. Der operierte Patient. - Bd.1 (Diseases of the pancreas. The operated patient. Vol 1.) TM-Verlag, Hameln 1989.
  40. Kunz O. Pankreatitis bei Hepatitis epidemica? (Pancreatitis associated with hepatitis epidemica?) Med. Klin. 1971; 66 (7): 243-245.
  41. Lankisch PG. Konservative Therapie der chronischen Pankreatitis. (Conservative therapy of chronic pancreatitis.) Med. Welt 1988; 39: 453-456.
  42. Lankisch PG, Lembcke B, Goke B, Creutzfeldt W. Therapie der pankreatogen Steatorrhoe: Bietet der Saureschutz fur Pankreasenzyme Vorteile? (Therapy of pancreatic steatorrhoea: is acid protection of pancreatic enzymes an advantage?) Tagung Dtsch. Ges. f. innere Med. 1983; 89: 864-867.
  43. Lankisch PG, Lembcke B, Goke B, Creutzfeldt W. Therapy of pancreatic steatorrhoea: Does acid protection of pancreatic enzymes offer any advantage? Z. Gastroenterologie 1986; 24 (12): 753-757.
  44. Lankisch PG, Lembcke B, Kirchhoff S, Hilgers R, Creutzfeldt W. Therapie der pankreatogenen Steatorrhoe. Vergleich zweier sauregeschutzter Enzympraparate. (Therapy of pancreatogenic steatorrhoea. Comparison of two acid-protected enzyme preparations.) Dtsch. Med. Wochenschr. 1988; 113:15-17.
  45. Lindenschmidt Th O. Sekretionsinsuffizienz des Magens und Pankreas bei Cholecystopathien. (Gastric and pancreatic insufficiency associated with cholecystopathy.) Klin. Wochenschr. 1956; 34 (19/20): 544-545.
  46. Marotta F, O'Keefe SJD, Marks IN, Girdwood A, Young G. Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating. Dig. Dis. Sci. 1989; 34 (3): 456-461.
  47. Meyer JH, Elasthoff J, Porter-Fink V, Dressman J, Amidon GL. Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterol. 1988; 94: 1315-1325.
  48. Meythaler F, Hofer E. Antwort zur Diagnose und Therapie der Pankreasinsuffizienz. (Answer to diagnosis and therapy of pancreatic insufficiency.) Landarzt 1963; 39: 1269-1270.
  49. Otte M. Diagnostischer Wert direkter und indirekter Pankreasfunktionsprufungen bei chronischer Pankreatitis. (Diagnostic value of direct and indirect tests of pancreatic function in chronic pancreatitis.) Dtsch. Med. Wochenschr. 1989; 114: 1662-1664.
  50. Pap A, Varro V. Replacement therapy in pancreatic insufficiency with a new pancreatin preparation respecting the physiological ratio of lipase/trypsin activity. Hepato-gastroenterol. 1988; 35: 83-86.
  51. Pap A, Korom M, Marosi E, Varro V. Requirements for successful pancreatic replacement therapy. Comparison of results with Creon and Panpur treatments. Orvosi Hetilap 1990; 131: 241.
  52. Pfennig P-M, Thies E, Lambrich E, Ridder P-H, Otte M. Therapie der exokrinen Pankreasinsuffizienz mit sauregeschutzten Pankreasenzymen. (Therapy of pancreatic exocrine insufficiency with acid protected pancreatic enzymes.) Therapiewoche 1985; 35 (7): 2475-2478.
  53. Pinho AC. Dispepsia e Terapeutica enzimatica de substituicao. (Pancreatic enzyme substitution in dyspepsia.) Cadernos Do Generalista 1990; VIII (78): 40-47.
  54. Reis A, Gromotka R. Substitutionsbehandlung von Verdauungsstorungen bei verschiedenen Oberbaucherkrankungen. (Replacement therapy of digestive disorders associated with various epigastric diseases.) Arztl. Praxis 1975; 27 (78): 3039-3041.
  55. Rosch W. Chronische Pankreatitis. (Chronic pancreatitis.) Dtsch. Arzteblatt 1979; 39: 2473-2481.
  56. Rosenberger J. Nachsorgeprobleme bei Patienten mit chronischer Pankreatitis. (Follow-up of patients with chronic pancreatitis.) Leber, Magen, Darm 1982; 12 (2): 80-84.
  57. Sarles J-C, Sarles H. Konservative und chirurgische Therapie der chronischen Pankreatitis. (Medical and surgical management of chronic pancreatitis.) Leber, Magen, Darm 1976; 6 (5): 294-299.
  58. Slaff J, Jacobson D, Tillman CR, Curington C, Toskes P. Protease-specific suppression of pancreatic exocrine secretion. Gastroenterol. 1984; 87: 44-52.
  59. Stanik H. Chronische Pankreatitis. (Chronic pancreatitis.) Fortschr. Med. 1975; 93 (30): 1467-1472.
  60. Stead RJ, Skypala I, Hodson ME, Batten JC. Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. Thorax 1987; 42 (7): 533-537.
  61. Steegmuller KW, Fischer R. Die totale Duodenopankreatektomie bei der chronischen Pankreatitis. (Total duodenopancreatectomy in chronic pancreatitis.) Z. Gastroenterol. 1980; 18: 633-638.
  62. Stephan U. Moderne Therapie der Mukoviszidose (zystische Fibrose). (Modern therapy of cystic fibrosis.) Therapiewoche 1975; 23: 3251-3253.
  63. Tillander H. Enzymsubstitution nach operativer Pankreasinsuffizienz. (Enzyme substitution after surgical pancreatic insufficiency.) Munch. Med. Wochenschr. 1970; 112 (9): 388-393.
  64. Tummler В. Molekularphysiologie der Mukoviszidose. (Molecular physiology of cystic fibrosis.) Med. Welt 1990; 41: 218-221.
  65. Vyas H, Matthew DJ, Milla PJ. A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis. A controlled study. Eur. J. Pediatr. 1990; 149: 241-243.
  66. Wagner E. Die Pathophysiologie der exokrinen Pankreasfunktion vor und nach Magenresektion vom Тур Billroth II. (Pathophysiology of exocrine pancreatic function before and after gastric resection of Billroth type II.) Dtsch. Med. Wochenschr. 1967; 92: 1016-1022.
  67. Wiesemann HG. Lungenfunktion bei Mukoviszidose. (Pulmonary function in cystic fibrosis.) Med. Welt 1990; 41: 222-225.
  68. Williams J, MacDonald A, Weller PH, Fields J, Pandov H. Two enteric coated microspheres in cystic fibrosis. Arch. Dis. Child. 1990; 65: 594-597.

Эффективность и безопасность препаратов Креон® (как и фармакологический профиль) систематически документировались с начала 1980-х годов.

Для удобства ориентации читателя, ниже перечислены избранные публикации с выделением наиболее важных "ключевых слов".

Галеновая форма/Размер частиц

  • Whitehead, A. M. (1998)
  • Meyer, J. H. (1988)
  • Mundlos, S. et al. (1991)
  • Kuhnelt, P. et al. (1996)
  • Layer, P. et al. (1992)
  • Norregard, P. et al. (1996)
  • Walters, M. P. and Littlewood, J. M. (1996)
  • Huwel, S. et al. (1996)
  • Lippold, В. С. (1998)

Креон® обладает преимуществом в отношении характеристик высвобождения и защиты от кислоты по сравнению с другими ферментными препаратами.

Существуют убедительные доказательства того, что частица меньшего чем 1.7 мм диаметра (критический размер 1.4 + 0.3 мм) обеспечивает одновременный проход препарата через привратник вместе с химусом. Минимикросферы представляют собой в настоящее время "идеальную лекарственную форму".

В том числе здоровые люди, с периодически возникающими жалобами после приема жирной пищи, могут принимать препарат.

  • Suarez, F. et al. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci 44:1317-1321 (1999)

"Традиционные" и растворимые в кишечнике

Препараты, покрытые растворимой в кишечнике оболочкой, значительно превосходят по эффективности "традиционные" препараты.

  • Abiodun, P. and Tolckmitt, W. Zur Behandlung der Pankreazinsuffizienz bei Mucovisz idose. (Treament of pancreatic insufficiency associated with cystic fibrosis.) Kinderarzt 13:1887-1892 (1982)
  • Biermann, H. et al. Durch modifizierten Saureschutz Verbesserung der Enzymtherapie bei Pankreazinsuffizienz (Improved enzyme therapy in pancreatic insufficiency with modified acid protection). Medvelt 36: 92-95 (1985)
  • Freise, J. and Horstkotte, H. Exokrine Pankreazinsuffizienz. Vergleich einer Substitutionstherapie mit einer nichtsaur-eresistenten und einer saureresistenten Enzymepraparation. (Pancreatic exocrine insufficiency. A comparison of supplementation with a non-enteric coated and an enteric coated enzyme preparation.) Fortschr Med 104:625-628 (1986)
  • Lankisch, P. G. et al. Therapy of pancreatic steatorrhoea: does acid protection of pancreatic enzymes offer any advantage? Z Gastroenterol 24: 753-757 (1986)
  • Aparisi, L. et al. Estudio de la efficacia de una nueva pancreatina microencapsulada f rente a un praparado convencional, en el tratamiento de la esteatorrea de origen pancreatico. (Efficacy study to compare a new microencapsulated pan-creatin with a conventional preparation in the treatment of steatorrhoea of pancreatic origin.) Rev Esp Enf Ap Digest 76: 25-30 (1989)
  • Henker, 1. et al. Mukoviszedose bei Kindern. Vergleich der Wirksamkeit zweier Pankreatinpraparate. (Cystic fibrosis in children. Comparison of the efficacy of two different pancreatic enzyme preparations.) Therapiewoche 39:2226-2229 (1989)

Таблетки и микросферы

  • Stead, R. J. et al. Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with a standard enteric coated preparation. Thorax 42: 533-537 (1987)
  • Beverley, D. W. et al. Comparison of four different pancreatic extracts in cystic fibrosis. Arch Dis Child 62: 564-568 (1987)
  • Pap, A. et al. Replacement therapy in pancreatic insufficiency with a new pancreatin preparation respecting the physiological ratio of lipase / trypsin activity. Hepato-gastroenterol 35: 83-86 (1988)
  • Herrerias, J. M. et al. Estudio comparative cruzado entre pancreatina en "pellets" у pancreatina en tabletas en pancreatitis cronica. (Comparative crossover study of pancreatin in pellets and pancreatin in tablets in chronic pancreatitis.) Rev Esp Enf Ap Digest 76: 651-653 (1989)
  • Vyas, H. et al. A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis: A controlled study. Eur J Pediatr - 149: 241-243 (1990)

Хотя препараты в виде таблеток все еще употребляются, средства, содержащие сферы (микро- и минимикросферы) расцениваются как препараты выбора. Распределение дозы в инкапсулированные сферы гарантирует ровное распределение активного вещества и лучшее перемешивание с пищевыми массами в желудке. Кроме того, эвакуация сфер из желудка вместе с пищей во время пищеварительной фазы и увеличение поверхности действия способствуют улучшению всасывания и пищеварения.

Уменьшение количества принимаемых капсул / Предпочтения больных

Количество имеющихся в продаже мощных ферментов в начале 1980-х годов отражало реальный прогресс в лечении экзокринной недостаточности поджелудочной железы. Для больных, нуждающихся в приеме большого количества липазы, стал реальностью более редкий прием лекарств, например, вместо 3 капсул стандартного Креона они начали принимать в день по одной капсуле Креона 25 000. Следовательно, большая часть пациентов выбрало для лечения мощные препараты. Удобство применения новых препаратов для больных является залогом успешного лечения.

  • George, D. E. et al. Comparison of two pancreatic enzyme supplements in patients with cystic fibrosis. Adv Ther 7:109-118 (1990)
  • Elliott, R. В. et al. A comparison of two pancreatic preparations in cystic fibrosis. NZ Med J 105:107-108 (1992)
  • Friesen, С. and Prestidge, С. Comparison of a highstrength pancreatic enzyme preparation and a standard-strength preparation in cystic fibrosis. Adv Ther 12: 236-244 (1995)
  • Braden, В. etal. (1997)
  • Robinson, P. J. and Natoli, G. (1998)

Муковисцидоз

  • Abiodun, P. and Tolckmitt, W. (1982)
  • Beverley, D. W. et al. (1987)
  • Stead, R.J. etal. (1987)
  • Henker.J.etal. (1989)
  • Vyas, H. et al. (1990)
  • George, D. E. etal. (1990)
  • Elliott, R. В. etal. (1992)
  • Hill, С. М. et al. Pancreatic enzyme supplementation in cystic fibrosis (Letter). Arch Dis Child 68:150 (1993)
  • Friesen, С. and Presidge, С. (1995)
  • De Boeck, К. et al. (1998)
  • Robinson, P. J. and Natoli, G. (1998)
  • Sinaasappel, М. et al. Double-blind, crossover study to prove the equivalence of Creon® 10000 Minimicrospheres (mms) versus Creon® 8000 micro-spheres (ms) in patients with cystic fibrosis (CF). (Abstract). Pediatr Pulmonol 536 (1998)

Хронический панкреатит

  • Gretzmacher, I. and Ruther, H. G. Maldigestion. Therapiewoche 33: 6776-6782 (1983)
  • Isaakson, G. and Ihse, I. Pain reduction by an oral pancreatic enzyme preparation in chronic pancreatitis. Dig Dis Sci 28: 97-102 (1983)
  • Biermann, H. etal. (1985)
  • Friese, J. and Horstkotte, H. (1986)
  • Lankisch, P. G. Conservative treatment of chronic pancreatitis. Digestion 37 (Supp11): 47-55 (1987)
  • Aparisi, L etal. (1989)
  • HerreriasJ.M. (1989)
  • Larvin, М. et al. Marked placebo responses in chronic pancreatitis: final results of a controlled trial of Creon® therapy (Abstract). Br J Surg 79: 457 (1992)
  • O'Keefe, S. J. D. et al. Double-blind, placebo-controlled parallel group study to evaluate the efficacy of Creon® 10000
  • Minimicrospheres vs. placebo in patients with pancreatic exocrine insufficiency due to chronic pancreatitis (Abstract).
  • Digestion 58 (SuppI 2): 54 (1997)
  • Gaia, E. et al. Double-blind, crossover study comparing the efficacy of Creon® 25000 versus Pancrease® in patients with chronic pancreatitis (Abstract). Digestion 60: 375 (1999)
  • Maim, U. et al. A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther 13: 951-957 (1999)

Заместительная терапия после хирургического вмешательства

  • Gretzmacher, I. and Ruther, H. G. (1983)
  • Armbrecht, U. et al. The benefit of pancreatic enzyme substitution after total gastrectomy. Aliment Pharmacol Ther 2: 493-500(1988)
  • Van Hoozen, C. М. et al. (1997)
  • Neoptolemos, J. P. et al. (1999)
  • Ghaneh, P. and Neoptolemos, J. P. Pancreatic exocrine insufficiency following pancreatic resection. Digestion 60 (SuppI 1): 104-110 (1999)
  • Bragelmann, R. et al. (1999)



Solvay Pharma Реклама: Здоровье и благополучие женщины после 40
Баннерная сеть Солвей-Фарма.ру
Адрес


Последнее обновление  4.01.2009 г.